

Evaluation of different recall periods for the US National

Clinical Trials

14, 255-263

DOI: [10.1177/1740774517698645](https://doi.org/10.1177/1740774517698645)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). <i>Journal of Patient-Reported Outcomes</i> , 2017, 1, 8.	0.9	44
2	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	8.2	82
3	Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey. <i>Supportive Care in Cancer</i> , 2018, 26, 1841-1849.	1.0	10
4	Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 56.	0.9	4
5	Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center. <i>Acta Haematologica</i> , 2018, 140, 194-202.	0.7	4
6	Different predictors of pain severity across age and gender of a Chinese rural population: a cross-sectional survey. <i>BMJ Open</i> , 2018, 8, e020938.	0.8	8
7	Incorporating Patient-Reported Outcomes Into Early-Phase Trials. , 2018, , 193-208.		3
8	Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 100-106.	0.9	11
9	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 19.	0.9	17
10	The development, usability, and reliability of the Electronic Patient Visit Assessment (ePVA) for head and neck cancer. <i>MHealth</i> , 2019, 5, 21-21.	0.9	6
11	Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. <i>Cancer</i> , 2019, 125, 2945-2954.	2.0	60
12	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. <i>Oncologist</i> , 2019, 24, 762-771.	1.9	56
13	Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X-linked protoporphyria. <i>JIMD Reports</i> , 2019, 50, 9-19.	0.7	15
14	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	0.7	26
15	Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 435-444.	1.1	2
16	Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 947-957.	1.0	97
17	Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO). <i>BMC Cancer</i> , 2020, 20, 442.	1.1	5
18	Multidimensional Pain Assessment Tools for Ambulatory and Inpatient Nursing Practice. <i>Pain Management Nursing</i> , 2020, 21, 416-422.	0.4	9

#	ARTICLE	IF	CITATIONS
19	Chemotherapy-induced nausea in a sample of gynaecological cancer patients: assessment issues and personal risk factors evaluation. <i>Supportive Care in Cancer</i> , 2020, 28, 5343-5351.	1.0	3
21	Preferences of Individuals With Cancer for Patient-Reported Outcome Measures. <i>Oncology Nursing Forum</i> , 2021, 48, 173-183.	0.5	2
22	Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer. <i>Clinical Trials</i> , 2021, 18, 408-416.	0.7	4
23	Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 47.	0.9	6
24	One-Year Quality of Life Post“Pneumonia Diagnosis in Japanese Adults. <i>Clinical Infectious Diseases</i> , 2021, 73, 283-290.	2.9	20
25	Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE _{v.7.0}). <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 81.	0.9	5
26	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 88.	0.9	19
27	Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. <i>JMIR Human Factors</i> , 2018, 5, e10070.	1.0	20
28	Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients’s and Clinicians’s Experiences. <i>Journal of Medical Internet Research</i> , 2020, 22, e14896.	2.1	24
29	Research Methods: Quality of Life and Patient-Reported Outcome Research in Geriatric Oncology. , 2018, , 1-10.		0
32	New Developments in the Use of Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 335-339.	0.8	4
33	Research Methods: Quality of Life and Patient-Reported Outcome Research in Geriatric Oncology. , 2020, , 1105-1113.		1
34	Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy “A prospective pilot study. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022, 21, 8-15.	0.6	6
35	Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study. <i>JMIR Formative Research</i> , 2022, 6, e27775.	0.7	2
36	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. <i>Cancers</i> , 2022, 14, 660.	1.7	3
37	Analysis of a Remote Monitoring Program for Symptoms Among Adults With Cancer Receiving Antineoplastic Therapy. <i>JAMA Network Open</i> , 2022, 5, e221078.	2.8	19
39	Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials. <i>Clinical Trials</i> , 2022, 19, 274-276.	0.7	3
40	Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events. <i>Clinical Trials</i> , 2022, 19, 267-273.	0.7	5

#	ARTICLE	IF	CITATIONS
41	Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). Tumori, 0, , 030089162210995.	0.6	3
42	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. Biomedicines, 2022, 10, 1334.	1.4	5
43	Autoavaliação de Sintomas pelo Paciente com Câncer: a Hora é Agora. Revista Brasileira De Cancerologia, 2022, 68, .	0.0	0
44	Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria: a pilot study (ePRO-AA-PNH). Annals of Hematology, 2023, 102, 199-208.	0.8	1
45	The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine. Frontiers in Oncology, 0, 12, .	1.3	4
46	Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE® to Provide Two Distinct and Complementary Perspectives. Patient Related Outcome Measures, 0, Volume 13, 249-258.	0.7	5
47	Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group. Lancet Oncology, The, 2023, 24, e86-e95.	5.1	13
48	Systematic Review of the Effect of a One-Day Versus Seven-Day Recall Duration on Patient Reported Outcome Measures (PROMs). Patient, 2023, 16, 201-221.	1.1	4
49	GSTM1 and GSTT1 polymorphisms associated with pain in a chemotherapy-induced peripheral neuropathy cohort. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
50	Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period. Quality of Life Research, 2023, 32, 2047-2058.	1.5	1
51	The iBLAD app protocol: a national, exploratory study on a multimodality smartphone app in bladder cancer for better understanding symptoms, quality of life and need for supportive care. Acta Oncologica, 2023, 62, 329-333.	0.8	0
52	Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease. Pharmaceuticals, 2023, 16, 512.	1.7	2